Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis

[1]  L. Dupont,et al.  Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study , 2017, Chest.

[2]  W. Dixon,et al.  Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA , 2017, RMD Open.

[3]  Fleming,et al.  ITS Annual Scientific Meeting 2016 , 2016, Irish Journal of Medical Science (1971 -).

[4]  W. Dixon,et al.  Smoking‐Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink , 2016, Arthritis care & research.

[5]  G. Cioffi,et al.  Disease activity and left ventricular systolic function in rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[6]  V. Cameron,et al.  Efficacy of a Rheumatoid Arthritis–Specific Smoking Cessation Program: A Randomized Controlled Pilot Trial , 2016, Arthritis care & research.

[7]  Shun-Chiao Chang,et al.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow‐Up: Results From the Nurses’ Health Study , 2016, Arthritis care & research.

[8]  A. Fabre,et al.  Sulfasalazine: A rare cause of acute eosinophilic pneumonia , 2016, Respiratory medicine case reports.

[9]  H. Harris,et al.  How to Motivate Patients with Rheumatoid Arthritis to Quit Smoking , 2016, The Journal of Rheumatology.

[10]  A. Barton,et al.  Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes , 2016, RMD Open.

[11]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[12]  Raveendhara R. Bannuru,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis care & research.

[13]  S. H. Flix,et al.  Enfermedad pulmonar intersticial inducida por hidroxicloroquina , 2015 .

[14]  C. Kelly,et al.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review , 2015, Therapeutic advances in musculoskeletal disease.

[15]  B. Elewski,et al.  Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis. , 2015, Journal of drugs in dermatology : JDD.

[16]  Shandra L. Protzko,et al.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.

[17]  U. Faubel.  SP0096 Deutsche Rheuma-Liga Supporting People to Find their Way through the Health System , 2015 .

[18]  P. Emery,et al.  THU0158 Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre , 2015 .

[19]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[20]  H. T. Fuzii,et al.  Formation of multiple pulmonary nodules during treatment with leflunomide , 2015, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[21]  V. Cameron,et al.  Identifying Barriers to Smoking Cessation in Rheumatoid Arthritis , 2015, Arthritis care & research.

[22]  W. Dixon,et al.  Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. , 2015, Best practice & research. Clinical rheumatology.

[23]  P. Emery,et al.  092. Efficacy and Safety of Rituximab in Rheumatoid Arthritis Patients with Concomitant Interstitial Lung Disease: 10-Year Experience at Single Centre , 2015 .

[24]  M. O’Donnell,et al.  Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials , 2015, BMJ : British Medical Journal.

[25]  G. Raghu,et al.  Rheumatoid arthritis-associated lung disease , 2015, European Respiratory Review.

[26]  G. de Luca,et al.  Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. , 2015, Seminars in arthritis and rheumatism.

[27]  E. Bendstrup,et al.  Rituximab-induced interstitial lung disease: five case reports , 2015, European clinical respiratory journal.

[28]  M. Cutolo,et al.  Smoking cessation advice by rheumatologists: results of an international survey. , 2014, Rheumatology.

[29]  Juan Li,et al.  A Metaanalysis of the Increased Risk of Rheumatoid Arthritis-related Pulmonary Disease as a Result of Serum Anticitrullinated Protein Antibody Positivity , 2014, The Journal of Rheumatology.

[30]  E. Mylonakis,et al.  Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Helena Canhão,et al.  FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries , 2014 .

[32]  W. Dixon,et al.  The safety of biologic therapies in RA-associated interstitial lung disease , 2014, Nature Reviews Rheumatology.

[33]  K. Yanaba,et al.  Successful experience of rituximab therapy for systemic sclerosis‐associated interstitial lung disease with concomitant systemic lupus erythematosus , 2014, The Journal of dermatology.

[34]  Joyce S Lee,et al.  Predictors of mortality in rheumatoid arthritis‐related interstitial lung disease , 2014, Respirology.

[35]  I. Glaspole,et al.  Prevalence and prognosis of unclassifiable interstitial lung disease , 2014, European Respiratory Journal.

[36]  B. Haraoui,et al.  Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. , 2014, Seminars in arthritis and rheumatism.

[37]  S. Proudman,et al.  Rheumatoid Arthritis and Lung Disease: From Mechanisms to a Practical Approach , 2014, Seminars in Respiratory and Critical Care Medicine.

[38]  J. Lewis,et al.  Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy , 2014, Annals of the rheumatic diseases.

[39]  D. M. van der Heijde,et al.  Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts , 2014, Annals of the rheumatic diseases.

[40]  B. Combe,et al.  Association of Tobacco Exposure and Reduction of Radiographic Progression in Early Rheumatoid Arthritis: Results From a French Multicenter Cohort , 2013, Arthritis care & research.

[41]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[42]  S. Gabriel,et al.  Incidence and Mortality of Obstructive Lung Disease in Rheumatoid Arthritis: A Population‐Based Study , 2013, Arthritis care & research.

[43]  M. Cottone,et al.  Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. , 2013, European journal of internal medicine.

[44]  M. A. van de Laar,et al.  Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. , 2013, Rheumatology.

[45]  R. Winchester,et al.  Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease , 2013, Annals of the rheumatic diseases.

[46]  E. Matteson,et al.  Trends in Serious Infections in Rheumatoid Arthritis , 2013, The Journal of Rheumatology.

[47]  A. Condliffe,et al.  Coexistence of Bronchiectasis and Rheumatoid Arthritis: Revisited , 2013, Respiratory Care.

[48]  A. Zelenetz,et al.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. , 2013, Clinical lymphoma, myeloma & leukemia.

[49]  Michael J Thun,et al.  50-year trends in smoking-related mortality in the United States. , 2013, The New England journal of medicine.

[50]  M. Ramos-Casals,et al.  Biologics-induced autoimmune diseases , 2013, Current opinion in rheumatology.

[51]  W. Dixon,et al.  Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population , 2012, Rheumatology.

[52]  F. Salaffi,et al.  Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. , 2012, Autoimmunity reviews.

[53]  M. Haroon,et al.  A case of severe pulmonary infiltration with eosinophilia (PIE) syndrome induced by sulphasalazine , 2012, International journal of rheumatic diseases.

[54]  M. Sugimoto,et al.  Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. , 2012, Respiratory medicine.

[55]  G. Cambridge,et al.  Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement , 2012 .

[56]  K. Põlluste,et al.  Compliance with treatment of rheumatoid arthritis , 2012, Rheumatology International.

[57]  T. Hartman,et al.  Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia , 2012 .

[58]  E. Lee,et al.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.

[59]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[60]  D. Lynch,et al.  Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. , 2012, Respiratory medicine.

[61]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[62]  Joyce S Lee,et al.  A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[63]  L. Murray,et al.  Smoking and Idiopathic Pulmonary Fibrosis , 2012, Pulmonary medicine.

[64]  D. Hansell,et al.  Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy , 2012, European Respiratory Journal.

[65]  P. Kiely,et al.  BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. , 2011, Rheumatology.

[66]  E. Chilvers,et al.  Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. , 2011, Rheumatology.

[67]  W. Dixon,et al.  The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses , 2011, Arthritis research & therapy.

[68]  Sun-Hee Kim,et al.  Recurrent pneumothorax associated with pulmonary nodules after leflunomide therapy in rheumatoid arthritis: a case report and review of the literature , 2011, Rheumatology International.

[69]  W. Grassi,et al.  [Severe drug hypersensitivity syndrome due to sulphasalazine in patient with rheumatoid arthritis]. , 2011, Reumatismo.

[70]  R. Burgos-Vargas,et al.  Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study , 2011, Clinical Rheumatology.

[71]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[72]  J. Ioannidis,et al.  Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. , 2011, Autoimmunity reviews.

[73]  S. Desmond,et al.  Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease. , 2011, Rheumatology.

[74]  Pierre-Antoine Gourraud,et al.  Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. , 2011, Joint, bone, spine : revue du rhumatisme.

[75]  G. Raghu,et al.  Rheumatoid arthritis-interstitial lung disease-associated mortality. , 2011, American journal of respiratory and critical care medicine.

[76]  A. de Lauretis,et al.  Review Series: Aspects of Interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? , 2011, Chronic respiratory disease.

[77]  É. Toussirot,et al.  Agents anti-TNFα et sarcoïdose , 2010 .

[78]  P. Kiely,et al.  BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. , 2010, Rheumatology.

[79]  J. Varga,et al.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management , 2010, Arthritis research & therapy.

[80]  C. V. van Gils,et al.  Risk factors for idiopathic orbital inflammation: a case–control study , 2010, British Journal of Ophthalmology.

[81]  D. Bilton,et al.  British Thoracic Society guideline for non-CFbronchiectasis , 2010, Thorax.

[82]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[83]  Cynthia S Crowson,et al.  Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. , 2010, Arthritis and rheumatism.

[84]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[85]  M. Hochberg,et al.  Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment , 2010, Arthritis research & therapy.

[86]  M. Niederman,et al.  Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial , 2010, BMJ : British Medical Journal.

[87]  D. Furst,et al.  Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials , 2010, The Journal of Rheumatology.

[88]  I. Donatelli,et al.  Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. , 2010, Clinical immunology.

[89]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[90]  T. E. King,et al.  Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease , 2009, European Respiratory Journal.

[91]  R. George,et al.  BTS guidelines for the management of community acquired pneumonia in adults: update 2009 , 2009, Thorax.

[92]  Y. Saeki,et al.  Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. , 2009, Rheumatology.

[93]  S. Pavy,et al.  Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. , 2009, Rheumatology.

[94]  B. Séroussi,et al.  Rituximab-induced lung disease: a systematic literature review , 2009, European Respiratory Journal.

[95]  D Emilie,et al.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. , 2009, Arthritis and rheumatism.

[96]  C. Turesson,et al.  High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. , 2009, Rheumatology.

[97]  K. Brown,et al.  Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA , 2009, Clinical Rheumatology.

[98]  E. Martı́n-Mola,et al.  Infectious complications of biologic agents. , 2009, Rheumatic diseases clinics of North America.

[99]  D. Sugiyama,et al.  Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies , 2009, Annals of the rheumatic diseases.

[100]  J. Schmutz,et al.  DRESS et hydroxychloroquine , 2008 .

[101]  S. Lane,et al.  Variation of immunological response in methotrexate-induced pneumonitis. , 2008, Rheumatology.

[102]  J. Vestbo,et al.  COPD-related morbidity and mortality after smoking cessation: status of the evidence , 2008, European Respiratory Journal.

[103]  G. Caldito,et al.  Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. , 2008, The Journal of rheumatology.

[104]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[105]  T Pullar,et al.  BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. , 2008, Rheumatology.

[106]  Chris Stenton,et al.  The MRC breathlessness scale. , 2008, Occupational medicine.

[107]  M. Hochberg,et al.  A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis , 2008, Arthritis research & therapy.

[108]  A. Volpe,et al.  Hydroxychloroquine-induced DRESS syndrome , 2008, Clinical Rheumatology.

[109]  C. Kelly,et al.  Acute lower respiratory tract infections in patients with rheumatoid arthritis. , 2007, The Journal of rheumatology.

[110]  M. Hudson,et al.  Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. , 2007, Rheumatology.

[111]  J. Choe,et al.  Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[112]  F. Andersohn,et al.  Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs , 2007, Annals of Internal Medicine.

[113]  L. Tay,et al.  Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects , 2007, Arthritis research & therapy.

[114]  C. Birbara,et al.  Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. , 2007, The Journal of rheumatology.

[115]  Y. Tomita,et al.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. , 2007, The Journal of rheumatology.

[116]  A. Silman,et al.  Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis , 2006, Annals of the rheumatic diseases.

[117]  Frederick Wolfe,et al.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.

[118]  E. Kimby.  Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.

[119]  D. Scott,et al.  Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. , 2005, Rheumatology.

[120]  E. Mendelson,et al.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers , 2005, Annals of the rheumatic diseases.

[121]  L. Jacobsson,et al.  Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. , 2005, Arthritis and rheumatism.

[122]  J. Gómez-Reino,et al.  Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. , 2005, Arthritis and rheumatism.

[123]  F. Martinez,et al.  Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification , 2005, Thorax.

[124]  Jennifer A. Roberts,et al.  A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. , 2004, The Journal of infectious diseases.

[125]  J. Biederer,et al.  Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis , 2004, European Radiology.

[126]  S. Ehlers,et al.  Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF , 2003, Annals of the rheumatic diseases.

[127]  G. Ben Amor,et al.  [Bronchiectasis in rheumatoid arthritis. High resolution computed pulmonary tomography]. , 2003, La Tunisie medicale.

[128]  S. Gabriel,et al.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years , 2003, Annals of the rheumatic diseases.

[129]  R. Long,et al.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. , 2003, The Lancet. Infectious diseases.

[130]  F. Martinez,et al.  Radiological versus histological diagnosis in UIP and NSIP: survival implications , 2003, Thorax.

[131]  K. Nichol,et al.  Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[132]  C. Barbatzas,et al.  Sulphasalazine and lung toxicity , 2002, European Respiratory Journal.

[133]  I. D. Johnston,et al.  American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias , 2002 .

[134]  K. Wood,et al.  Corticosteroid supplementation for adrenal insufficiency. , 2002, JAMA.

[135]  J. Dawson,et al.  Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests , 2001, Thorax.

[136]  F. Breedveld,et al.  Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients. , 2000, Arthritis and rheumatism.

[137]  G. Hosie,et al.  Teaching rheumatology in primary care , 2000, Annals of the rheumatic diseases.

[138]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[139]  G. Choquet-Kastylevsky,et al.  Treatment of Drug-Induced Agranulocytosis with Haematopoietic Growth Factors , 1999, BioDrugs.

[140]  U. Wagner,et al.  Perturbation of the T cell repertoire in rheumatoid arthritis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[141]  D. Wendling,et al.  Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. , 1998, Revue du rhumatisme.

[142]  J. Kremer,et al.  Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. , 1997, Arthritis and rheumatism.

[143]  D. Schwartz,et al.  Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. , 1996, Arthritis and rheumatism.

[144]  L. Espinoza,et al.  Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[145]  A. Teufel,et al.  Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. , 1994, The Journal of rheumatology.

[146]  M. Weinblatt,et al.  Bronchiectasis: A Late Feature of Severe Rheumatoid Arthritis , 1994, Medicine.

[147]  A. van der Heide,et al.  Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. , 1994, Annals of the rheumatic diseases.

[148]  J. Owen,et al.  High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. , 1994, British journal of rheumatology.

[149]  M. McMahon,et al.  Bronchiectasis and rheumatoid arthritis: a clinical study. , 1993, Annals of the rheumatic diseases.

[150]  R. Cooper,et al.  HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. , 1993, British journal of rheumatology.

[151]  R. Adair,et al.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. , 1991, The New England journal of medicine.

[152]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.

[153]  S. Wahl,et al.  Humoral immune function in severe, active rheumatoid arthritis. , 1987, Clinical immunology and immunopathology.

[154]  R. Hoffmann,et al.  Pneumococcal Vaccine Immunization of Patients with Renal Impairment 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[155]  F. Cosio,et al.  Serum antibody responses of high-risk children and adults to vaccination with capsular polysaccharides of Streptococcus pneumoniae. , 1981, Reviews of infectious diseases.

[156]  G. Kolarz,et al.  Seropositive rheumatoid arthritis associated with decreased diffusion capacity of the lung. , 1976, Annals of the rheumatic diseases.

[157]  A. Fischer,et al.  Lung Disease in Rheumatoid Arthritis , 2018, Respiratory Medicine.

[158]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[159]  S. Hernández Flix,et al.  [Interstitial lung disease induced by hydroxychloroquine]. , 2015, Medicina clinica.

[160]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[161]  E. D. del Valle,et al.  [Rituximab-induced interstitial lung disease]. , 2013, Medicina.

[162]  T. Wada,et al.  [A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept]. , 2012, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[163]  Nicholas S. Kelley,et al.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[164]  S. Wedrén,et al.  Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. , 2011, Arthritis and rheumatism.

[165]  R. Wilson,et al.  Bronchiectasis and autoimmune disease , 2011 .

[166]  N. Kearney,et al.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.

[167]  K. Kubo,et al.  A case of organizing pneumonia induced by tocilizumab. , 2011, Internal medicine.

[168]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[169]  P. Tak,et al.  Clinical and epidemiological research , 2011 .

[170]  J. Morović-Vergles.  [Safety of rituximab in patients with rheumatoid arthritis]. , 2010, Reumatizam.

[171]  M. Khamashta,et al.  Autoimmune diseases induced by biological agents: a double-edged sword? , 2010, Autoimmunity reviews.

[172]  S. Agarwal,et al.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. , 2010, Arthritis and rheumatism.

[173]  G. Specchia,et al.  Spontaneous remission of “methotrexate-associated lymphoproliferative disorders” after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature , 2009, Medical oncology.

[174]  A. Barbaud,et al.  [Hydroxychloroquine and DRESS]. , 2008, Annales de dermatologie et de venereologie.

[175]  C. Kelly,et al.  Methotrexate pneumonitis precipitated by switching from oral to parenteral administration. , 2008, Rheumatology.

[176]  G. Jönsson,et al.  Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. , 2006, Rheumatology.

[177]  D. Wendling,et al.  DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. , 2005, Joint, bone, spine : revue du rhumatisme.

[178]  T. Kishida,et al.  Pulmonary infiltration and eosinophilia associated with sulfasalazine therapy for ulcerative colitis: a case report and review of literature. , 1992, Internal medicine.

[179]  A. Bamji,et al.  Rheumatoid arthritis and chronic bronchial suppuration. , 1985, Scandinavian journal of rheumatology.

[180]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[181]  Author for correspondence: Dr. AU Wells Interstitial Lung Disease Unit , 2022 .

[182]  W. Dixon,et al.  Extended Report , 2022 .